The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | The tumor-myeloid axis as a predictor of response to immunotherapy in NSCLC
Adrian Sacher, MD, Princess Margaret Cancer Centre, Toronto, Canada, talks on the tumor-myeloid axis as a predictor of response to immunotherapy in patients with non-small cell lung cancer (NSCLC). Patients with NSCLC treated immunotherapy can have excellent responses, however, the vast majority of patients have a poor response. Investigation into poor responses to immunotherapy revealed the presence and expansion of myeloid cells in the peripheral circulation of patients as a predictor of response. Ongoing research aims to characterize the factors that cause the myeloid cells to proliferate and how this can induce resistance to immunotherapy. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
